Terms: = Ovarian cancer AND TRA
15 results:
1. TCR CDR3-antigen chemical complementarity associated with poor ovarian cancer outcomes: A vestigial immune response to early cancer antigens?
Barker VR; Varkhedi M; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Am J Reprod Immunol; 2023 Jan; 89(1):e13639. PubMed ID: 36317868
[TBL] [Abstract] [Full Text] [Related]
2. HER-2-mediated nano-delivery of molecular targeted drug potently suppresses orthotopic epithelial ovarian cancer and metastasis.
Wang Z; Guo B; Yue S; Zhao S; Meng F; Zhong Z
Int J Pharm; 2022 Sep; 625():122126. PubMed ID: 35995316
[TBL] [Abstract] [Full Text] [Related]
3. Sessile serrated adenoma of the appendix coexists with anaplastic carcinoma mural nodules originating from ovarian mucinous tumors: A case report.
Wang P; Wang XJ; Wang XY; Wang CY
Niger J Clin Pract; 2022 Jun; 25(6):964-966. PubMed ID: 35708441
[TBL] [Abstract] [Full Text] [Related]
4. Detecting tra-1-60 in cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent.
White JM; Kuda-Wedagedara AN; Wicker MN; Spratt DE; Schopperle WM; Heath E; Viola NT
Mol Pharm; 2020 Apr; 17(4):1139-1147. PubMed ID: 32069422
[TBL] [Abstract] [Full Text] [Related]
5. HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of ovarian Tumor.
Ding L; Gu W; Zhang Y; Yue S; Sun H; Cornelissen JJLM; Zhong Z
Biomacromolecules; 2019 Oct; 20(10):3855-3863. PubMed ID: 31513391
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract] [Full Text] [Related]
7. Human mass balance study and metabolite profiling of
van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
[TBL] [Abstract] [Full Text] [Related]
8. Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer.
Sato K; Hanaoka H; Watanabe R; Nakajima T; Choyke PL; Kobayashi H
Mol Cancer Ther; 2015 Jan; 14(1):141-50. PubMed ID: 25416790
[TBL] [Abstract] [Full Text] [Related]
9. Anti-tumor activity of an anti-DR5 monoclonal antibody, tra-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
Bevis KS; McNally LR; Sellers JC; Della Manna D; Londoño Joshi A; Amm H; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2011 Apr; 121(1):193-9. PubMed ID: 21211830
[TBL] [Abstract] [Full Text] [Related]
10. Effect of tra-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.
Frederick PJ; Kendrick JE; Straughn JM; Della Manna DL; Oliver PG; Lin HY; Grizzle WE; Stockard CR; Alvarez RD; Zhou T; LoBuglio AF; Buchsbaum DJ
Int J Gynecol Cancer; 2009 Jul; 19(5):814-9. PubMed ID: 19574765
[TBL] [Abstract] [Full Text] [Related]
11. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.
Beumer JH; Garner RC; Cohen MB; Galbraith S; Duncan GF; Griffin T; Beijnen JH; Schellens JH
Invest New Drugs; 2007 Aug; 25(4):327-34. PubMed ID: 17347871
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy of anti-death receptor 5 (DR5) antibody (tra-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.
Estes JM; Oliver PG; Straughn JM; Zhou T; Wang W; Grizzle WE; Alvarez RD; Stockard CR; LoBuglio AF; Buchsbaum DJ
Gynecol Oncol; 2007 May; 105(2):291-8. PubMed ID: 17303227
[TBL] [Abstract] [Full Text] [Related]
13. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
[TBL] [Abstract] [Full Text] [Related]
14. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) ovarian cancer Study Group.
Hilpert F; Stähle A; Tomé O; Burges A; Rossner D; Späthe K; Heilmann V; Richter B; du Bois A;
Support Care Cancer; 2005 Oct; 13(10):797-805. PubMed ID: 16025262
[TBL] [Abstract] [Full Text] [Related]
15. Luminescence applications for chemotherapeutic drug development.
Andreotti PE; Caceres G; Zamkina R; Dauphinée M
Recent Results Cancer Res; 2003; 161():3-12. PubMed ID: 12528794
[TBL] [Abstract] [Full Text] [Related]